NHERF1 and breast carcinoma: Furthermore, in contrast to the previously described work, Song et al. have reported that EBP50 immunoreactivity in breast cancer was positively associated with tumor stage and lymph node involvement[14], prompting others to suggest that its role in oncogenesis or tumor suppression may vary with cellular location, with a membranous or apical distribution supporting a tumor suppressor function and a cytoplasmic distribution conferring oncogenic properties [5].